ArticleInternational journal of nanomedicine2021
Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Metal-organic frameworks for hepatocellular carcinoma therapy and mechanism.Frontiers in pharmacology · 2022Pooled it
- Protein Modifications for Cellular Protein Delivery.Chemical reviews · 2026Review
- Advances in metal-organic frameworks (MOFs) for nanotheranostics: from targeted drug delivery to multimodal imaging.Mikrochimica acta · 2026Review
- Targeting ferroptosis induction via nanomaterials in hepatocellular carcinoma: an insight into mechanism and therapeutic potential.Journal of nanobiotechnology · 2026Review
- Ferroptosis nanomedicine for cancer therapy: strategies and challenges.Frontiers in molecular biosciences · 2026Review
- Sorafenib-Drug Delivery Strategies in Primary Liver Cancer.Journal of functional biomaterials · 2025Review
- Bibliometric analysis of nanoparticle research for diagnostics and therapeutics in hepatocellular carcinoma.Discover nano · 2025Review
- Review
- Therapeutic types and advantages of functionalized nanoparticles in inducing ferroptosis in cancer therapy.Annals of medicine · 2024Review
- Ferroptosis: A double-edged sword.Cell death discovery · 2024Review
- Glucose-Regulated Protein 78 Targeting ICG and DOX Loaded Hollow FeInternational journal of nanomedicine · 2024Article
- Ferroptosis targeting natural compounds as a promising approach for developing potent liver cancer agents.Frontiers in pharmacology · 2024Review
- Advances in Ferroptosis-Inducing Agents by Targeted Delivery System in Cancer Therapy.International journal of nanomedicine · 2024Review
- Aptamer-mediated hollow MnODrug delivery · 2023Article
- Exploring Sorafenib and Simvastatin Combination for Ferroptosis-Induced Cancer Treatment: Cytotoxicity Screening, In Vivo Efficacy, and Safety Assessment.AAPS PharmSciTech · 2023Article
- Inaugurating a novel adjuvant therapy in urological cancers: Ferroptosis.Cancer pathogenesis and therapy · 2023Review
- Ferroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2023Review
- Recent trends in emerging strategies for ferroptosis-based cancer therapy.Nanoscale advances · 2023Review
- Iron as a therapeutic target in chronic liver disease.World journal of gastroenterology · 2023Review
- The advancements in targets for ferroptosis in liver diseases.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHepatocellular carcinoma (HCC) is one of the most common fatal cancers, with no curative therapy available. The concept of ferroptosis is attracting increasing attention in cancer research. Herein, we describe the use of a nanodevice as an effective strategy for inducing ferroptosis to manage HCC.
methodsTo improve ferroptosis-induced treatment of HCC, we constructed sorafenib (sor)-loaded MIL-101(Fe) nanoparticles (NPs) [MIL-101(Fe)@sor] and evaluated the efficacy of ferroptosis-based HCC therapy after co-administration with the iRGD peptide both in vitro and in vivo.
resultsThe prepared MIL-101(Fe) NPs have several promising characteristics including drug-loading, controllable release, peroxidase activity, biocompatibility, and T2 magnetic resonance imaging ability. MIL-101(Fe)@sor NPs significantly induced ferroptosis in HepG2 cells, increased the levels of lipid peroxidation and malondialdehyde, and reduced those of glutathione and glutathione peroxidase 4 (GPX-4). The in vivo results showed that the MIL-101(Fe)@sor NPs significantly inhibited tumor progression and decreased GPX-4 expression levels, with negligible long-term toxicity. Meanwhile, co-administration of MIL-101(Fe)@sor NPs with iRGD significantly accelerated ferroptosis.
conclusionOur findings suggest that MIL-101(Fe)@sor NPs co-administered with iRGD are a promising strategy for inducing HCC ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.